These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 8540088)

  • 1. No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation.
    Hägglund H; Ringdén O; Ljungman P; Winiarski J; Ericzon B; Tydén G
    Transplant Proc; 1995 Dec; 27(6):3535. PubMed ID: 8540088
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA)].
    Yoshimi A; Kato K; Maeda N; Matsuyama T; Kojima S
    Rinsho Ketsueki; 2000 Feb; 41(2):103-8. PubMed ID: 10723238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatal hemorrhage after recombinant tissue plasminogen activator therapy for hepatic veno-occlusive disease complicating autologous BMT.
    Otheo de Tejada E; Maldonado MS; Camarero C; Muñoz A
    Bone Marrow Transplant; 1994 Jul; 14(1):176-7. PubMed ID: 7951113
    [No Abstract]   [Full Text] [Related]  

  • 4. Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients.
    Leahey AM; Bunin NJ
    Bone Marrow Transplant; 1996 Jun; 17(6):1101-4. PubMed ID: 8807121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of tissue plasminogen activator in the treatment of veno-occlusive liver disease after bone marrow transplantation.
    Terra SG; Spitzer TR; Tsunoda SM
    Pharmacotherapy; 1997; 17(5):929-37. PubMed ID: 9324182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant tissue plasminogen activator (rTPA) for hepatic veno-occlusive disease after allogeneic BMT in a pediatric patient.
    Feldman L; Gabai E; Milovic V; Jaimovich G
    Bone Marrow Transplant; 1995 Nov; 16(5):727. PubMed ID: 8547875
    [No Abstract]   [Full Text] [Related]  

  • 7. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia.
    Lee JH; Lee KH; Choi SJ; Min YJ; Kim JG; Kim S; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
    Bone Marrow Transplant; 2000 Sep; 26(6):657-62. PubMed ID: 11041568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double treatment of severe hepatic veno-occlusive disease after allogeneic peripheral blood progenitor cell transplantation with recombinant tissue plasminogen activator.
    Söhngen D; Bauser U; Boogen C; Aul C; Frieling T; Germing U; Schneider P; Kobbe G; Heyll A
    Thromb Haemost; 1997 Oct; 78(4):1299-300. PubMed ID: 9365005
    [No Abstract]   [Full Text] [Related]  

  • 9. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA).
    Baglin TP; Harper P; Marcus RE
    Bone Marrow Transplant; 1990 Jun; 5(6):439-41. PubMed ID: 2369685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment.
    Bajwa RP; Cant AJ; Abinun M; Flood TJ; Hodges S; Hale JP; Skinner R
    Bone Marrow Transplant; 2003 Apr; 31(7):591-7. PubMed ID: 12692627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation.
    Schriber J; Milk B; Shaw D; Christiansen N; Baer M; Slack J; Tezcan H; Wetzler M; Herzig G
    Bone Marrow Transplant; 1999 Dec; 24(12):1311-4. PubMed ID: 10627640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of veno-occlusive disease with recombinant tissue plasminogen activator in a patient requiring peritoneal dialysis.
    Simpson DR; Browett PJ; Doak PB; Palmer SJ
    Bone Marrow Transplant; 1994 Oct; 14(4):635-6. PubMed ID: 7858540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of hepatic veno-occlusive disease (VOD) in pediatric patients: retrospective analysis in 6 AIEOP-BMT (Italian Pediatric Hematology Oncology Association-Bone Marrow Transplantation Group) Centers.
    Miniero R; Vassallo E; Soldano S; Nesi F; Vai S; Balduzzi A; Varotto S; Dallorso S; Prete A; Arcese W
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():157-9. PubMed ID: 8932820
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1.
    Higashigawa M; Watanabe M; Nishihara H; Tabata N; Azuma E; Ido M; Ito M; Sakurai M
    Leuk Res; 1995 Jul; 19(7):477-80. PubMed ID: 7637394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation--clinical and immunological considerations.
    Schlitt HJ; Tischler HJ; Ringe B; Raddatz G; Maschek H; Dietrich H; Kuse E; Pichlmayr R; Link H
    Bone Marrow Transplant; 1995 Sep; 16(3):473-8. PubMed ID: 8535323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A trial use of prostaglandin E1 for prevention of hepatic veno-occlusive disease after allogeneic bone marrow transplantation].
    Morio S; Oh H; Kogure K; Ishii H; Ishii A; Nakaseko C; Ikegami T; Kawano E; Matsuura Y; Nishimura M
    Rinsho Ketsueki; 1994 Sep; 35(9):846-52. PubMed ID: 7967053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic veno-occlusive disease with severe capillary leakage after peripheral stem cell transplantation: treatment with recombinant plasminogen activator and C1-esterase inhibitor concentrate.
    Heying R; Nürnberger W; Spiekerkötter U; Göbel U
    Bone Marrow Transplant; 1998 May; 21(9):947-9. PubMed ID: 9613790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: impact on coagulation profile.
    Goldberg SL; Shubert J; Rao AK; Redei I; Klumpp TR; Mangan KF
    Bone Marrow Transplant; 1996 Sep; 18(3):633-6. PubMed ID: 8879629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation.
    Abecasis MM; Conceição Silva JP; Ferreira I; Guimarães A; Machado A
    Bone Marrow Transplant; 1999 Apr; 23(8):843-6. PubMed ID: 10231151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteplase for hepatic veno-occlusive disease after bone marrow transplantation.
    Ringdén O; Wennberg L; Ericzon BG; Kallman R; Aström M; Duraj F; Söderdahl G; Tydén G; Groth CG
    Lancet; 1992 Aug; 340(8818):546-7. PubMed ID: 1354293
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.